Terms: = Thyroid cancer AND RAF1, Raf-1, 5894, P04049, ENSG00000132155, c-Raf, CRAF AND Treatment
25 results:
1. Decabromodiphenyl ether exposure reduces dabrafenib sensitivity of papillary thyroid carcinoma harboring BRAF
Wang X; Cui X; Wang Y; Wang Q; Sun F; Liu Z
Toxicology; 2024 May; 504():153807. PubMed ID: 38641160
[TBL] [Abstract] [Full Text] [Related]
2. Case report: Complete response of an anaplastic thyroid carcinoma patient with
Gui L; Zhu Y; Li X; He X; Ma T; Cai Y; Liu S
Front Immunol; 2023; 14():1178682. PubMed ID: 37122752
[TBL] [Abstract] [Full Text] [Related]
3. RREB1 promotes the development of parafollicular carcinogenesis through the Ras-raf-1-ELK3 signaling pathway.
Ma S; Wang H; Li W; Yan Z; Luo X; Lu P
Nucleosides Nucleotides Nucleic Acids; 2022; 41(10):972-981. PubMed ID: 35737446
[TBL] [Abstract] [Full Text] [Related]
4. The Association of the BRAF-V600E Mutation with the Expression of the Molecular Markers in the Primary Tumor and Metastatic Tissue in Papillary thyroid cancer.
Spirina LV; Chizhevskaya SY; Kovaleva IV; Kondakova IV
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2017-2024. PubMed ID: 34319022
[TBL] [Abstract] [Full Text] [Related]
5. Systemic review on B-Raf
Chavda J; Bhatt H
Eur J Med Chem; 2020 Nov; 206():112675. PubMed ID: 32798788
[TBL] [Abstract] [Full Text] [Related]
6. Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.
Desai J; Gan H; Barrow C; Jameson M; Atkinson V; Haydon A; Millward M; Begbie S; Brown M; Markman B; Patterson W; Hill A; Horvath L; Nagrial A; Richardson G; Jackson C; Friedlander M; Parente P; Tran B; Wang L; Chen Y; Tang Z; Huang W; Wu J; Zeng D; Luo L; Solomon B
J Clin Oncol; 2020 Jul; 38(19):2140-2150. PubMed ID: 32182156
[TBL] [Abstract] [Full Text] [Related]
7. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract] [Full Text] [Related]
8. Screening for thyroid cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Lin JS; Bowles EJA; Williams SB; Morrison CC
JAMA; 2017 May; 317(18):1888-1903. PubMed ID: 28492904
[TBL] [Abstract] [Full Text] [Related]
9. Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated thyroid cancer.
Wei WJ; Sun ZK; Shen CT; Song HJ; Zhang XY; Qiu ZL; Luo QY
Theranostics; 2017; 7(4):987-1001. PubMed ID: 28382170
[TBL] [Abstract] [Full Text] [Related]
10. The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in thyroid cancer.
Beadnell TC; Mishall KM; Zhou Q; Riffert SM; Wuensch KE; Kessler BE; Corpuz ML; Jing X; Kim J; Wang G; Tan AC; Schweppe RE
Mol Cancer Ther; 2016 Aug; 15(8):1952-63. PubMed ID: 27222538
[TBL] [Abstract] [Full Text] [Related]
11. Selective use of sorafenib in the treatment of thyroid cancer.
Pitoia F; Jerkovich F
Drug Des Devel Ther; 2016; 10():1119-31. PubMed ID: 27042004
[TBL] [Abstract] [Full Text] [Related]
12. Hepatocellular carcinoma cases with high levels of c-raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence.
Lei J; Zhong J; Hao J; Liu Z; Zhang P; Wu L; Yan L; Zhu J; Zeng Y; Li B; Wen T; Wang W
Oncotarget; 2016 Jul; 7(27):42598-42607. PubMed ID: 26981887
[TBL] [Abstract] [Full Text] [Related]
13. Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells.
Hanly EK; Tuli NY; Bednarczyk RB; Suriano R; Geliebter J; Moscatello AL; Darzynkiewicz Z; Tiwari RK
Oncotarget; 2016 Feb; 7(8):8676-87. PubMed ID: 26735176
[TBL] [Abstract] [Full Text] [Related]
14. Aggressive thyroid cancer: targeted therapy with sorafenib.
Corrado A; Ferrari SM; Politti U; Mazzi V; Miccoli M; Materazzi G; Antonelli A; Ulisse S; Fallahi P; Miccoli P
Minerva Endocrinol; 2017 Mar; 42(1):64-76. PubMed ID: 26112458
[TBL] [Abstract] [Full Text] [Related]
15. Sorafenib and thyroid cancer.
Fallahi P; Ferrari SM; Santini F; Corrado A; Materazzi G; Ulisse S; Miccoli P; Antonelli A
BioDrugs; 2013 Dec; 27(6):615-28. PubMed ID: 23818056
[TBL] [Abstract] [Full Text] [Related]
16. Phase I/II RAF kinase inhibitors in cancer therapy.
Turajlic S; Ali Z; Yousaf N; Larkin J
Expert Opin Investig Drugs; 2013 Jun; 22(6):739-49. PubMed ID: 23642225
[TBL] [Abstract] [Full Text] [Related]
17. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
Cohen SM; Mukerji R; Timmermann BN; Samadi AK; Cohen MS
Am J Surg; 2012 Dec; 204(6):895-900; discussion 900-1. PubMed ID: 23231932
[TBL] [Abstract] [Full Text] [Related]
18. Xanthohumol inhibits the neuroendocrine transcription factor achaete-scute complex-like 1, suppresses proliferation, and induces phosphorylated ERK1/2 in medullary thyroid cancer.
Cook MR; Luo J; Ndiaye M; Chen H; Kunnimalaiyaan M
Am J Surg; 2010 Mar; 199(3):315-8; discussion 318. PubMed ID: 20226902
[TBL] [Abstract] [Full Text] [Related]
19. Regulation of cell-cell contact molecules and the metastatic phenotype of medullary thyroid carcinoma by the raf-1/MEK/ERK pathway.
Ning L; Kunnimalaiyaan M; Chen H
Surgery; 2008 Dec; 144(6):920-4; discussion 924-5. PubMed ID: 19040998
[TBL] [Abstract] [Full Text] [Related]
20. Calcitonin targets extracellular signal-regulated kinase signaling pathway in human cancers.
Nakamura M; Han B; Nishishita T; Bai Y; Kakudo K
J Mol Endocrinol; 2007 Dec; 39(6):375-84. PubMed ID: 18055485
[TBL] [Abstract] [Full Text] [Related]
[Next]
